Chronic Lymphocytic Leukemia
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
No PFS or OS events were reported for treatment-naive elderly patients.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
A variety of cognitive impairments are common in the elderly US population, with as many as 14% of individuals over 70 being affected by dementia.
Umbralisib has shown improved isoform selectivity over currently used PI3Kδ inhibitors.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
The impact of cancer-specific stress on psychological and physical functioning among patients with CLL was not previously well-understood.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Researchers used a reporter assay to determine which immune-mediating receptors were activated by rituximab, obinutuzumab, and ofatumumab.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.
Researchers investigated whether PET-CT SUV has clinical utility among patients with CLL receiving venetoclax who failed therapy with ibrutinib or idelalisib.
Gary Gordon, MD, PhD, discusses latest findings at the ASH 2017 meeting in Atlanta.
Danelle James, MD, discusses the changing landscape at the ASH 2017 meeting in Atlanta.
Elias Jabbour, MD, discusses the latest developments in the treatment of acute and chronic leukemia from the ASH 2017 meeting.
Alessandra Tedeschi, MD, discusses the latest findings on ibrutinib for treatment of chronic lymphocytic leukemia (CLL).
Cancer Therapy Advisor interviews Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), about the LLS's research directions and how the treatment of hematologic malignancies is changing.
A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
In order to optimize therapeutic sequencing among patients with CLL, 5 patient aspects must be considered.
In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.
From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.
CONTINUUM suggests that maintenance therapy with lenalidomide is an effective way for prolonging progression-free survival without affecting potential subsequent lines of therapy.
Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.
The high cost of CAR-T therapy concerns patient advocates who worry about the "financial toxicity" implications for patients and their families. But these cancer immunotherapies might offer an excellent value for clinical oncology, proponents claim.
Results of this double-blind, phase 3 study report the effect of lenalidomide maintenance therapy on the risk of disease progression in patients with CLL.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy